Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the transaction, the insider owned 93,969 shares in the company, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Anne Lesage also recently made the following trade(s):
- On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The shares were sold at an average price of $35.48, for a total transaction of $988,898.56.
- On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total value of $245,244.85.
- On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The shares were sold at an average price of $35.07, for a total value of $371,742.00.
- On Wednesday, April 29th, Anne Lesage sold 3,700 shares of Pharvaris stock. The shares were sold at an average price of $30.08, for a total value of $111,296.00.
- On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The stock was sold at an average price of $30.26, for a total value of $580,992.00.
- On Thursday, April 30th, Anne Lesage sold 21,700 shares of Pharvaris stock. The stock was sold at an average price of $30.26, for a total value of $656,642.00.
- On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.
- On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total value of $225,375.00.
- On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.
Pharvaris Stock Down 1.8%
PHVS stock traded down $0.63 during mid-day trading on Wednesday, reaching $33.95. The company had a trading volume of 376,128 shares, compared to its average volume of 409,202. The stock has a market capitalization of $2.22 billion, a P/E ratio of -10.68 and a beta of -2.34. Pharvaris N.V. has a one year low of $17.05 and a one year high of $35.90. The stock’s 50-day simple moving average is $30.90 and its two-hundred day simple moving average is $28.21.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on PHVS. Citizens Jmp reduced their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Royal Bank Of Canada dropped their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. UBS Group set a $74.00 price objective on shares of Pharvaris in a research note on Wednesday, May 13th. Wedbush boosted their target price on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Finally, Citigroup restated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.64.
View Our Latest Analysis on PHVS
Institutional Investors Weigh In On Pharvaris
A number of large investors have recently bought and sold shares of PHVS. General Atlantic L.P. increased its position in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the last quarter. Foresite Capital Management IV LLC lifted its position in shares of Pharvaris by 8.3% in the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after buying an additional 368,000 shares during the last quarter. venBio Partners LLC lifted its position in shares of Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after buying an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. boosted its stake in shares of Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after acquiring an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP boosted its stake in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares in the last quarter.
About Pharvaris
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Stories
- Five stocks we like better than Pharvaris
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
